Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer

Published:2018-11-23 Issue:1 Volume:10 Page:47-53
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Zhang Qing¹,Wu Chunyan²,Ding Wei³,Zhang Zhihong⁴,Qiu Xueshan⁵,Mu Dianbin⁶,Zhang Haiqing⁷,Xi Yanfeng⁸,Zhou Jianhua⁹,Ma Liheng¹⁰,Fu Shijun¹⁰,Gao Min¹⁰,Wang Bo¹¹,Deng Juan¹¹,Lin Dongmei¹²,Zhang Jie¹

Affiliation:

1. Department of Pathology; Shanghai Chest Hospital, Shanghai Jiao Tong University; Shanghai China

2. Department of Pathology; Shanghai Pulmonary Hospital, Tongji University School of Medicine; Shanghai China

3. Department of Pathology; Second Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou China

4. Department of Pathology; Jiangsu Province Hospital; Nanjing China

5. Department of Pathology; The First Hospital of China Medical University; Shenyang China

6. Department of Pathology; Shandong Cancer Hospital Affiliated with Shandong University, Shandong Academy of Medical Science; Jinan China

7. Department of Pathology; Beijing Chest Hospital, Capital Medical University; Beijing China

8. Department of Pathology; Affiliated Tumor Hospital of Shanxi Medical University; Taiyuan China

9. Department of Pathology; Xiangya Hospital, School of Basic Medicine, Central South University; Changsha China

10. Medical Affairs Department; Pfizer Oncology; Shanghai China

11. Amoy Diagnostics Co., Ltd.; Xiamen China

12. Department of Pathology; Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12899/fullpdf

Reference45 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

5. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project;Lung Cancer;2024-08

2. Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country;Cancer Management and Research;2024-07

3. The rapidly changing field of predictive biomarkers of non-small cell lung cancer;Pathology and Oncology Research;2024-06-17

4. Ros1 Fusions in Resected Stage I-Iii Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project;2024

5. Progress of non-small-cell lung cancer with ROS1 rearrangement;Frontiers in Molecular Biosciences;2023-12-22